Information Provided By: 
Fly News Breaks for September 4, 2015
MRK
Sep 4, 2015 | 07:20 EDT
After meeting with four senior Merck executives, SunTrust says that the selloff in the stock over concerns about the company's Januvia franchise are overdone. The firm expects the company's diabetes drugs to generate over $8.5B in revenue in 2020, up from less than $6B currently, through the launch of several new treatments within the next two years. It is upbeat on the outlook for the company's Keytruda cancer treatment and reiterates a $72 price target and Buy rating.
News For MRK From the Last 2 Days
There are no results for your query MRK
